For years, the 2018 Farm Bill created a federal distinction that helped establish an entirely new category of cannabinoid products.
Hemp was defined by a 0.3% delta-9 THC concentration limit on a dry-weight basis. That framework separated hemp from marijuana under the federal Controlled Substances Act and allowed a large market of hemp-derived products to develop.
Manufacturers subsequently used hemp biomass and extracts to produce CBD products, cannabinoids, beverages, gummies, edibles, tinctures, topicals and other consumer products.
The regulatory environment is now changing.
Congress enacted legislation in November 2025 that narrows the federal definition of hemp. The new framework replaces the delta-9-only approach with a total THC standard, excludes certain synthetic or externally manufactured cannabinoids, and establishes a 0.4-milligram combined THC-per-container limit for covered final hemp-derived cannabinoid products.
The transition has also changed again. Legislation enacted in September 2026 limits the application of portions of the 2025 hemp amendments until December 11, 2026, giving Congress additional time to address the broader regulatory framework.
For manufacturers, the important point is that this is no longer simply a question of whether a product contains less than 0.3% delta-9 THC.
The regulatory definition of the raw material, intermediate extract and finished product all need to be evaluated.
From the “Farm Bill Loophole” to a New Regulatory Framework
The phrase “hemp loophole” is commonly used to describe an interpretation of the 2018 Farm Bill under which products could remain within the federal hemp definition if they contained no more than 0.3% delta-9 THC, even if they contained other intoxicating cannabinoids.
The Congressional Research Service has described this interpretation and noted the growth of products containing cannabinoids such as delta-8 THC. These products appeared in formats including gummies, drinks and candies.
That distinction became increasingly important to manufacturers.
A product could be derived from federally defined hemp while still containing cannabinoids capable of producing intoxicating effects.
Congress’s 2025 legislation directly addresses that issue by changing the definition of hemp.
Under the amended framework, hemp is subject to a 0.3% total THC concentration limit, including THCA, rather than relying only on delta-9 THC. The law also addresses cannabinoids with effects similar to THC as determined under the statute.
This represents a fundamental change in how companies need to evaluate cannabinoid materials.
What Changed Under the New Federal Definition?
Several changes are particularly important for extraction companies and downstream manufacturers.
- Total THC Replaces Delta-9 THC as the Central Measurement
The 2018 framework focused on delta-9 THC.
The amended framework uses total THC, including THCA, and incorporates other cannabinoids with similar effects under the statutory framework.
This matters because an extraction operation can no longer look exclusively at a delta-9 result when evaluating the future federal status of a material.
For manufacturers, analytical testing programs may therefore need to account for:
- Delta-9 THC
- THCA
- Other relevant THC-class cannabinoids
- Cannabinoids identified under the federal framework
- Production-stage and finished-product concentrations
The change also increases the importance of analytical methods, laboratory qualification, sampling plans and documentation.
- A 0.4-Milligram Limit Applies to Covered Final Products
The amended definition excludes final hemp-derived cannabinoid products containing more than 0.4 milligrams combined total of THC and other cannabinoids with similar effects per container.
The definition of container is tied to the innermost packaging or vessel directly contacting the final product and intended for retail sale.
That distinction creates a major manufacturing consideration.
A product that previously qualified under a percentage-based hemp standard could face a very different compliance analysis once the finished-product limit is measured in milligrams per container.
For products such as beverages, gummies and other consumables, manufacturers will need to evaluate the relationship between:
extract potency → batch formulation → serving size → number of servings → container size → final cannabinoid content.
This is not simply a laboratory issue. It becomes a formulation, packaging, quality-control and production-planning issue.
Extraction Businesses Face a Particularly Important Challenge
The new rules are significant for extraction companies because intermediate materials are treated differently from finished consumer products.
The 2025 law excludes certain intermediate hemp-derived cannabinoid products containing more than 0.3% combined total THC and specified similar-effect cannabinoids. It also excludes intermediate and final products containing cannabinoids that cannot naturally be produced by the cannabis plant or that are naturally occurring but were synthesized or manufactured outside the plant.
That creates a critical question for extractors:
What is the federal legal status of the material being produced before it ever reaches a consumer-product manufacturer?
An extraction facility therefore cannot treat compliance as something that begins at packaging.
The process itself matters.
Companies may need to document:
- Biomass source and chain of custody
- Incoming cannabinoid profile
- Extraction method
- Solvent or processing system
- Post-extraction processing
- Conversion or chemical modification
- Intermediate material specifications
- Batch testing
- Final formulation
- Storage and segregation
- Shipment documentation
For facilities handling multiple cannabinoid streams, segregation and identification procedures may become increasingly important.
Synthetic and Converted Cannabinoids Add Another Layer
The new federal definition also excludes certain cannabinoids that are not capable of being naturally produced by Cannabis sativa, as well as cannabinoids that can naturally occur but were synthesized or manufactured outside the plant.
This is particularly relevant to businesses whose processes involve chemical conversion.
The distinction between:
plant-derived → extracted → purified
and
plant-derived → chemically converted → modified cannabinoid
can have regulatory consequences.
Manufacturers should therefore map the complete material flow rather than evaluating only the source of the original biomass.
A certificate stating that the starting material was hemp may not answer the regulatory question for a downstream cannabinoid.
The 2026 Timeline Is More Complicated Than It First Appeared
The original 2025 legislation established a one-year transition period, with the major hemp-definition changes scheduled for November 12, 2026.
Congress subsequently passed additional legislation in September 2026.
The new measure limits the application of portions of the 2025 changes until December 11, 2026. Congressional statements describe this as a delay of the broader hemp restrictions, while legal analyses have noted that the statutory language is more precise: it temporarily limits which portions of the 2025 amendments apply during the interim period.
For operators, that distinction matters.
As of September 24, 2026, the regulatory picture is therefore still in transition.
Companies should not treat December 11 as proof that the underlying federal changes have been repealed. They have not.
Nor should companies assume that the current 2018 framework will remain permanently in place.
Congress Is Still Considering Alternatives
The 2025 legislation did not end the legislative debate.
Congressional proposals have included approaches that would repeal the new hemp definition, change THC thresholds, or establish a federal regulatory framework for hemp-derived cannabinoid products. The Congressional Research Service identified several such proposals, including H.R. 6209, S. 2112 and S. 3474.
H.R. 6209, for example, would repeal Section 781 of the 2025 law. The bill was introduced in November 2025 and referred to the House Agriculture Committee.
Another approach emerged in 2026 through the Lawful Hemp Protection Act, H.R. 9830, which would preserve lawful hemp commerce while establishing additional consumer protections. The bill was introduced in July 2026 and referred to multiple House committees.
These proposals illustrate an important point for businesses:
The direction of federal hemp policy remains subject to congressional action.
Manufacturers should plan around enacted requirements while actively monitoring legislation rather than making major capital decisions based solely on proposed bills.
FDA Oversight Does Not Disappear
The federal hemp debate is sometimes discussed as though changing the definition of hemp automatically determines whether a consumer product can legally be marketed.
It does not.
The 2018 Farm Bill preserved FDA authority over hemp-derived products under the Federal Food, Drug, and Cosmetic Act. FDA continues to regulate cannabis-derived ingredients and products within its jurisdiction regardless of whether a material qualifies as hemp under agricultural and controlled-substance laws.
FDA has also stated that it has approved only certain prescription cannabis-derived or cannabis-related drugs and has not established a general approval pathway for ordinary CBD foods, beverages and dietary supplements.
For manufacturers, this means there are multiple regulatory questions, not one:
- Is the source material legally hemp?
- Does the cannabinoid remain within the federal hemp definition?
- Is the ingredient permitted for its intended use?
- Does the finished product comply with FDA requirements?
- Does the product comply with applicable state law?
- Are labeling and marketing claims appropriate?
- Does the facility operate under the appropriate food, dietary supplement, cosmetic or other quality system?
A product can therefore face regulatory problems even if its THC concentration satisfies one particular federal threshold.
State Regulations Add Another Layer of Complexity
Federal policy is only one part of the compliance picture.
States have developed their own approaches to hemp and cannabinoid products, including restrictions on intoxicating hemp products, age requirements, testing standards, labeling rules, licensing requirements and retail controls.
The National Conference of State Legislatures maintains a state cannabis legislation database covering enacted measures involving hemp and low-THC products. The database was updated September 14, 2026.
That creates a practical challenge for national brands.
A formulation that works in one state may not be suitable for another.
Manufacturers selling across multiple jurisdictions should maintain a state-by-state regulatory matrix covering:
- Product category
- Cannabinoid limits
- Testing requirements
- Age restrictions
- Packaging
- Labeling
- Registration or licensing
- Distribution channels
- Advertising restrictions
- Effective dates
This information should be tied directly to product development and quality systems rather than maintained as a separate legal document that manufacturing teams rarely see.
What Manufacturers Should Be Doing Now
The uncertainty surrounding federal hemp policy does not eliminate the need for operational planning.
In fact, it makes disciplined planning more important.
Conduct a Product-by-Product Regulatory Audit
Do not evaluate the portfolio as one category.
Review each SKU individually, including:
- Cannabinoid source
- Extraction process
- Cannabinoid concentration
- Total THC
- THCA
- Serving size
- Container size
- Intended use
- Packaging
- Label claims
- States where sold
The objective is to identify which products could be affected by the federal definition changes and which may have separate FDA or state-law issues.
Map the Entire Manufacturing Process
For extraction businesses, create a material-flow map from incoming biomass through final shipment.
Identify where cannabinoid concentrations change and where chemical transformations occur.
This can expose compliance risks that are invisible when a company looks only at the finished product.
Strengthen Testing and Documentation
Laboratory testing becomes more important as regulatory definitions become more specific.
Manufacturers should evaluate laboratory qualifications, analytical methods, sampling procedures, specifications, certificates of analysis and batch-release procedures.
Testing should support actual manufacturing decisions rather than simply generate a certificate for the customer.
Review Facility Segregation
Facilities producing multiple cannabinoid products may need stronger controls around:
- Raw-material identification
- Production scheduling
- Equipment cleaning
- Material segregation
- Label control
- Work-in-progress storage
- Finished-product release
These controls are particularly important when different product lines have different regulatory requirements.
Evaluate Reformulation Scenarios
Brands should not wait for the final regulatory deadline before modeling alternative formulations.
For affected products, manufacturers can evaluate potential scenarios such as:
- Lower-THC formulations
- Non-intoxicating cannabinoid products
- Different ingredient systems
- Different serving sizes
- Different packaging configurations
- State-specific product versions
- Transition into regulated cannabis channels where applicable
The purpose is not to assume a particular regulatory outcome, but to understand the operational consequences of each potential pathway.
What This Means for Investors and Business Owners
The changing hemp definition also affects how companies should evaluate the businesses and facilities operating in this sector.
Revenue generated from a single class of intoxicating hemp-derived products may carry a different regulatory risk profile than revenue generated from a diversified portfolio.
For investors and acquirers, due diligence should therefore extend beyond revenue and EBITDA.
Important questions include:
- Which SKUs generate the majority of revenue?
- Which cannabinoids are used?
- Where do those cannabinoids originate?
- Are they extracted, converted or synthesized?
- What percentage of revenue depends on intoxicating products?
- Which states represent the largest markets?
- What testing systems are in place?
- Are production records complete?
- What regulatory registrations or licenses are required?
- Can the facility manufacture alternative products?
- How quickly could the operation reformulate?
- Are equipment and processes adaptable to other product categories?
For facilities, flexibility may become an important component of long-term value.
A plant designed exclusively around one regulatory pathway may face greater disruption than a facility capable of producing multiple compliant product categories.
A Regulatory Shift Is Also a Facility-Planning Issue
The hemp market has increasingly moved toward consumer packaged goods manufacturing.
That means regulatory changes affect more than legal departments.
They can influence:
Facility layout.
Material segregation, storage and production flows may need to change.
Equipment selection.
Extraction, purification and formulation equipment may need to support different products or process streams.
Quality systems.
Batch records, testing, release procedures and traceability become increasingly important.
Packaging operations.
Container definitions and cannabinoid limits can directly affect filling, labeling and packaging configurations.
Utilities and process systems.
A facility transitioning between product categories may require changes to HVAC, sanitation, water, compressed air or other supporting systems.
Future expansion.
Facility designs should account for regulatory uncertainty where practical instead of locking the operation into one narrow product category.
This is where regulatory strategy and process engineering increasingly overlap.
The Hemp Market Is Not Simply Disappearing
It is important not to confuse the end of one regulatory framework with the end of hemp as an industry.
Industrial hemp remains specifically addressed under the amended federal framework, including applications involving fiber, grain, seed-derived materials, certain immature plants and research.
At the same time, the future of cannabinoid products remains subject to congressional action, federal implementation and state-level regulation.
The market may therefore evolve rather than simply disappear.
Some manufacturers may reformulate.
Others may shift toward non-intoxicating products, industrial hemp applications or other botanical and functional ingredients.
Some businesses may pursue regulated cannabis channels where permitted.
Others may focus on products with clearer food, cosmetic or dietary-supplement pathways.
The appropriate strategy will depend on the company’s products, processes, markets and regulatory obligations.
Conclusion: Manufacturers Need to Plan for Multiple Outcomes
The federal hemp market is entering a period of significant regulatory change.
The 2018 Farm Bill framework allowed hemp to be defined primarily by a 0.3% delta-9 THC threshold. The 2025 legislation moves federal law toward total THC, addresses certain synthetic or externally manufactured cannabinoids, and establishes a 0.4-milligram-per-container limit for covered final hemp-derived cannabinoid products.
A September 2026 federal funding measure has created additional time and narrowed the immediate application of portions of those changes through December 11, 2026, but it has not resolved the underlying policy debate.
For extraction companies, brands, investors and manufacturers, the practical response is not to wait for the final headline.
It is to understand the materials moving through the facility, verify the applicable regulatory requirements, strengthen testing and documentation, evaluate product alternatives, and design operations that can adapt as the federal and state frameworks develop.
The most important question for manufacturers is no longer simply:
“Does this product contain less than 0.3% delta-9 THC?”
The more useful question is:
“Does our entire material, process, product, facility and distribution model remain compliant under the regulatory framework that will apply to our business?”
That is the question companies should be answering before the next regulatory deadline arrives.
